IMPACT Therapeutics
IMPACT is a Shanghai biotech built around DNA damage response drugs; its PARP inhibitor senaparib met its phase 3 endpoint as maintenance in ovarian cancer and is approved in China.
Overview
IMPACT Therapeutics, headquartered in Shanghai, develops inhibitors of the DNA damage response. Its PARP inhibitor senaparib (IMP4297) improved progression-free survival as first-line maintenance in advanced ovarian cancer in the phase 3 FLAMES trial and gained Chinese approval, and its Wee1 and ATR inhibitors follow in earlier trials. Its trials are registered on ClinicalTrials.gov under IMPACT as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyTelik
Shares Pivotal (registrational) trial, Clinical trial, Ovarian cancer and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyGrifols
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.